Central nervous effects of Exenatide i.v. vs. NaCl 0.9% on regulation of hunger and satiety in obesity and type 2 diabetes: an fMRI study. Amendment 1: increase of dosage.
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Exenatide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms Neuroimaging and Obesity
- 10 Jun 2017 Biomarkers information updated
- 06 Jul 2012 Actual initiation date (13 Jan 2010) added as reported by German Clinical Trials Register.
- 21 Apr 2012 Planned number of patients changed from 20 to 40 as reported by European Clinical Trials Database.